Picton Mahoney Asset Management Sells 96,721 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Picton Mahoney Asset Management lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 13.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 617,892 shares of the company’s stock after selling 96,721 shares during the period. Picton Mahoney Asset Management owned about 0.05% of Teva Pharmaceutical Industries worth $12,483,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after acquiring an additional 4,732 shares during the period. Focus Partners Wealth lifted its position in Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after purchasing an additional 1,739 shares during the period. Assetmark Inc. boosted its stake in Teva Pharmaceutical Industries by 137.2% during the second quarter. Assetmark Inc. now owns 20,075 shares of the company’s stock worth $336,000 after buying an additional 11,613 shares in the last quarter. Bank of Montreal Can increased its holdings in Teva Pharmaceutical Industries by 15.9% in the 2nd quarter. Bank of Montreal Can now owns 475,937 shares of the company’s stock valued at $7,977,000 after buying an additional 65,191 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Teva Pharmaceutical Industries by 4.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,682,837 shares of the company’s stock valued at $28,204,000 after buying an additional 73,141 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TEVA. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Scotiabank lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Jefferies Financial Group upped their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Barclays increased their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Blackstone Life Sciences agreed to provide $400 million to fund development of duvakitug (TL1A antibody), lowering capital risk for Teva’s late‑stage IBD program and accelerating a potential new specialty biologic growth engine. Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug
• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and nudged its price target higher to $41, signaling continued analyst confidence and providing a visible upside reference for investors. Benzinga coverage of Piper Sandler
• Neutral Sentiment: Coverage highlighting generic-drug headwinds also notes Teva’s strategic push into complex generics and biosimilars as a hedge against price pressure—this supports longer-term growth but doesn’t remove near-term margin risk. 3 Generic Drug Stocks to Watch Despite Industry Headwinds
• Neutral Sentiment: Broader industry commentary about AI adoption in pharma could benefit Teva over time through R&D efficiency and manufacturing optimization, but it’s a longer‑horizon factor rather than an immediate catalyst. Pharmaceutical Executive Daily: Pharma Industry’s AI Adoption
• Negative Sentiment: An executive (EVP Eliyahu Sharon Kalif) disclosed a large sale of 345,810 shares (~$11.6M at the trade price), which can be interpreted by some investors as insider profit‑taking and can weigh on sentiment. Teva EVP Sells 345,810 Shares
• Negative Sentiment: High‑profile investor Stanley Druckenmiller trimmed his TEVA position per 13F filings, a notable name‑level reduction that can be read as profit‑taking and may reduce momentum among discretionary institutional buyers. Billionaire Stanley Druckenmiller Dumped Teva
• Negative Sentiment: A dividend-focused piece recommends an alternative high-yield competitor over Teva, which could damp demand from income investors who are comparing yields and stability. Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $32.87 on Thursday. The firm’s 50 day simple moving average is $33.03 and its 200 day simple moving average is $26.07. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a market capitalization of $37.79 billion, a price-to-earnings ratio of 27.39, a P/E/G ratio of 10.80 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company’s revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the completion of the transaction, the executive vice president owned 57,478 shares in the company, valued at approximately $1,933,559.92. This represents a 85.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Roberto Mignone sold 77,400 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the transaction, the director directly owned 367,600 shares of the company’s stock, valued at approximately $11,116,224. This trade represents a 17.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 767,870 shares of company stock worth $23,888,014. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.